Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 85K | 37K | 21K | 33K | 54K |
| Gross Profit | 8K | -4K | -4K | -4K | 21K |
| Operating Income | -1M | -1M | -3M | -3M | -1M |
| EBITDA | -1M | -1M | -3M | -3M | -1M |
| Net Income | -1M | -1M | -3M | -3M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0014
-6.67% today
1Y Change
-44.00%
Window
Jun 23, 2025 → Jun 11, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Univec, Inc. (UNVC) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.00 and down 44.0% across the available one-year price window (Jun 23, 2025 → Jun 11, 2026). Baseline metrics include revenue growth of +131.0%, EPS growth of +200.0%, a dividend yield of 0.0%. What stands out right now is revenue +131.0%, EPS +200.0%, free cash flow -28175.0% with operating margin -1495.6% and ROIC 7.8%. Valuation already assumes a fairly strong business story at price/sales 59.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines UNVC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UNVC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
UNVC Max Drawdown
-70.21%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for UNVC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$53.7K
+61.9% YoY
FY Net Income
-$1.3M
+49.7% YoY
Free Cash Flow
-$4.0M
-126.9% YoY
Revenue Growth
+131.0%
EPS Growth
+200.0%
Gross Margin
11.2%
Net Margin
-1429.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 85K | 37K | 21K | 33K | 54K |
| Gross Profit | 8K | -4K | -4K | -4K | 21K |
| Operating Income | -1M | -1M | -3M | -3M | -1M |
| EBITDA | -1M | -1M | -3M | -3M | -1M |
| Net Income | -1M | -1M | -3M | -3M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 0 | 0 | 0 | 341 |
| Total Assets | 32K | 34K | 32K | 1M | 3M |
| Total Liabilities | 18M | 16M | 15M | 14M | 14M |
| Shareholder Equity | -18M | -16M | -15M | -12M | -12M |
| Total Debt | 1M | 1M | 1M | 1M | 1M |
| Net Debt | 1M | 1M | 1M | 1M | 1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4M
-124.9% YoY
Capital Expenditures
34K
Free Cash Flow
4M
-126.9% YoY
Key ratios
Gross Margin
11.2%
Operating Margin
-1495.6%
Net Margin
-1429.6%
ROE
7.1%
Debt / Equity
-0.08x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.